



Gazette

ISSUE ID: 0000/2025/J/17
CROSS BORDER MOBILITY GAZETTE
08 October 2025

CRO GAZETTE, WEDNESDAY, 08 October 2025

CROSS BORDER MOBILITY SUBMISSIONS RECEIVED BETWEEN 01-OCT-25 AND 07-OCT-25							
Company Number	Company Name	Document	Date of Receipt	Company Number	Company Name	Document	Date of Receipt
558224	Pearl Pharmaceuticals Holdings Designated Activity Company	CBC1	03/10/2025				

European Union (Cross-Border Conversions, Mergers and Divisions) Regulations 2023

Notice is hereby given that in accordance with Regulation 12 of the European Union (Cross-Border Conversions, Mergers and Divisions) Regulations 2023, which gives effect to Directive (EU) 2017/1132 and Directive (EU) 2019/2121, and for the purpose of giving further effect to Article 8 of Directive 2008/104/EC, notice was received by the Registrar of Companies on 3rd October 2025 of a proposed conversion between the following companies:

PEARL PHARMACEUTICALS HOLDINGS DESIGNATED ACTIVITY COMPANY (a designated activity company incorporated in the Republic of Ireland under registration number 558224) and

Pearl Pharmaceuticals Holdings B.V.

a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid)

The Form CBC1, which contains the details required by Regulation 12(1)(c), is set out below.

The Draft Terms of the proposed conversion and the notice to the members, creditors and employees can be obtained from the Registrar of Companies at [CORE \(cro.ie\)](https://www.cro.ie)

Registrar of Companies

CBC1 Notice of Proposed Cross Border Conversion

Regulation 12(1) of the European Communities (Cross-Border Conversions, Mergers and Divisions) Regulations 2023

Submission Reference Number

SR6859178

Company Details

Company Number	558224
Company Name	PEARL PHARMACEUTICALS HOLDINGS DESIGNATED ACTIVITY COMPANY

Draft Terms and Notice

Copies of the Draft Terms are available for inspection at this web address, namely:

Copies provided

Proposed Converted Company Details

Proposed name	Pearl Pharmaceuticals Holdings B.V.
Proposed legal form	Private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid)
Proposed location of the registered office	Herengracht 450, 1017 CA Amsterdam, the Netherlands

Submission Attachments

Type	Description
Rights of employees, creditors and members for the Company CBC1	Form CBC1 - Attachment 1.pdf
Draft terms CBC1	Draft Terms of Conversion (3).docx.pdf
Notice to creditors, members and employees CBC1	Regulation 12(1)(b) Notice.pdf
Additional Particulars - Rights of Employees, Creditors and Members of Converted Company CBC1	Form CBC1 - Attachment 2(1023848192.1).pdf

Verification Details

Signature Method	Signature Page Upload
Signature Type	Director (Company)
Person Name	Neil Crawford

Presenter Details	
Presenter Name	Katie O'Rourke(DENTONS IRELAND LEGAL SERVICES LIMITED)
Presenter Address	Dentons Ireland, 20 Kildare Street, Dublin 2, DUBLIN, Ireland
Presenter Email	katie.orourke@dentons.com
DX number	
DX exchange	

Signature Page

Submission Reference Number:


SR6859178

CBC1 Notice of Proposed Cross Border Conversion

Related Entity Details

Name (or Proposed Name): PEARL PHARMACEUTICALS HOLDINGS DESIGNATED ACTIVITY
COMPANY
Number (if applicable): 558224

Signature of the person(s) who is (are) certifying that the information provided is correct

Please sign here 

Neil Crawford

Director (Company)

October 3, 2025

Date – This must be the date the officer signed the form.

DE4D7F3228C6C8891427EB6B4878770A

Legal References:

Collective Citations

Companies Act 2014